# US 7,744,878 B2 · Antibodies that bind to cancer-associated antigen CD46 and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,744,878 B2
- Document ID: US7744878B2
- Status: Granted
- Kind: B2
- Application number: 11/524,344
- Filed: 2006-09-19
- Published: 2007-06-07
- Granted: 2010-06-29
- Earliest claimed: 2001-10-16
- Assignees: Raven Biotechnologies, Inc.
- Inventors: Jennie P. Mather
- Web page: https://patentgrep.com/patent/US7744878B2

## CPC

- C07K 16/30: from tumour cells
- A61P 35/00: Antineoplastic agents
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/77: Internalization into the cell
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung, prostate, colon, kidney, and pancreas. Methods of diagnosing and treating various cancers by using antibodies such as mPA7 directed against this antigen are also disclosed.

## Claims

### Claim 1

A method of inhibiting growth of cancerous cells in a human individual comprising administering to the individual an effective amount of a composition comprising: (i) a chimeric or humanized antibody and (ii) a pharmaceutically acceptable excipient, wherein:
(A) said chimeric or humanized antibody comprises the three complementarity determining regions (CDRs) from the heavy chain and the three complementarity determining regions (CDRs) from the light chain of antibody mPA7 produced by a host cell with a deposit number of ATCC No. PTA-3706, and further comprises constant regions sufficient to induce an active immune response against cancerous cells
(B) said chimeric or humanized antibody specifically binds to the human CD46 antigen at the epitope recognized by antibody mPA7;
wherein said cancerous cells express said human CD46 antigen having the epitope recognized by antibody mPA7 on their cell surface, and bind said chimeric or humanized antibody, which induces an active immune response against said cancerous cells and inhibits their growth.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody is linked to a therapeutic agent.

### Claim 3 (depends on 1)

The method of claim 1, wherein the cancerous cells are prostate.

### Claim 4 (depends on 1)

The method of claim 1, wherein the antibody is a humanized antibody that comprises said three CDRs from the heavy chain and said three CDRs of the light chain of antibody mPA7 grafted into a human supporting framework region.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody is a chimeric antibody that comprises heavy chain and light chain constant regions from constant regions of a human antibody.

### Claim 6 (depends on 2)

The method of claim 2, wherein the therapeutic agent is a toxin, a radioactive compound, or a chemotherapeutic agent.